(Q36884566)

16 August 2017

1 reference

title

Can mTOR inhibitors reduce the risk of late kidney allograft failure? (English)

1 reference

16 August 2017

Claudio Ponticelli

1 reference

16 August 2017

publication date

17 July 2007

1 reference

16 August 2017

published in

Transplant International

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

2-10

1 reference

Multiple pathways to allograft rejection

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

The natural history of chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Risk factors for late kidney allograft failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Enhanced cytomegalovirus infection in atherosclerotic human blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Infection in organ-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Gastrointestinal complications in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Angiogenesis and endothelial cell repair in renal disease and allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

21 January 2018

Coronary-artery stents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Post-transplant malignancy: the role of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Rapamycin is an effective inhibitor of human renal cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Therapeutic targets: MTOR and related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Conversion from cyclosporine to sirolimus in stable renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00524.X

10.1111/J.1432-2277.2007.00524.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference